Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
No immediate clinical implications for rheumatic autoimmunity; leaves open structural targeting of U1-snRNP for mechanistic and therapeutic research.
The U1 small nuclear ribonucleoprotein particle (snRNP) is a target of autoreactive B cells and T cells in several rheumatic diseases including systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD). We propose that inherent structural properties of this autoantigen complex, including common RNA-binding motifs, B and T-cell epitopes, and a unique stimulatory RNA molecule, underlie its susceptibility as a target of the autoimmune response. Immune mechanisms that may contribute to overall U1-snRNP immunogenicity include epitope spreading through B and T-cell interactions, apoptosis-induced modifications, and toll-like receptor (TLR) activation through stimulation by U1-snRNA. We conclude that understanding the interactions between U1-snRNP and the immune system will provide insights into why certain patients develop anti-U1-snRNP autoimmunity, and more importantly how to effectively target therapies against this autoimmune response.
No takes yet. Share an insight, caveat, or question.
Kattah et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: